Relevant_synapse OP t1_iybp4zt wrote on November 30, 2022 at 5:01 AM

Reply to comment by arsenal09490 in Alzheimer’s Drug In Development, Lecanemab, May Benefit Some Patients But Carries Risks of Brain Swelling and Bleeding by Relevant_synapse

Did you see the reports of the two patients who had massive brain hemorrhages and died during the open label extension? One was an E4 noncarrier who was heparinized for an MI and the other was an E4 homozygote who got tPA for a stroke.

Presented here: https://twitter.com/JacobPlieth/status/1597770771606429698?s=20&t=EUU4CuKWkmzyva1QQH9d3g

arsenal09490 t1_iybpqh3 wrote on November 30, 2022 at 5:07 AM

No, I have not had a chance to look at those reports yet. Are they published or just announced in the press release?

Relevant_synapse OP t1_iybq2ec wrote on November 30, 2022 at 5:10 AM

Not sure about the first case. Per this article in Science Insider, the second case has at least been written up?

https://www.science.org/content/article/second-death-linked-potential-antibody-treatment-alzheimer-s-disease